Europe • Frankfurt Stock Exchange • FRA:AYJ • FR0004056851
The current stock price of AYJ.DE is 3.93 EUR. In the past month the price increased by 0.36%. In the past year, price increased by 42.39%.
ChartMill assigns a technical rating of 7 / 10 to AYJ.DE. When comparing the yearly performance of all stocks, AYJ.DE is one of the better performing stocks in the market, outperforming 83.66% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE. AYJ.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months AYJ.DE reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -1180% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.86% | ||
| ROE | -80.02% | ||
| Debt/Equity | 0.89 |
11 analysts have analysed AYJ.DE and the average price target is 7.34 EUR. This implies a price increase of 86.69% is expected in the next year compared to the current price of 3.93.
For the next year, analysts expect an EPS growth of -607% and a revenue growth -6.69% for AYJ.DE
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
VALNEVA SE
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
Employees: 695
Phone: 33228073710
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
The current stock price of AYJ.DE is 3.93 EUR. The price decreased by -1.45% in the last trading session.
AYJ.DE does not pay a dividend.
AYJ.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
VALNEVA SE (AYJ.DE) has a market capitalization of 340.76M EUR. This makes AYJ.DE a Small Cap stock.
You can find the ownership structure of VALNEVA SE (AYJ.DE) on the Ownership tab.